-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Analyzing Cue Health (NASDAQ:HLTH) and Nautilus Biotechnology (NASDAQ:NAUT)
Analyzing Cue Health (NASDAQ:HLTH) and Nautilus Biotechnology (NASDAQ:NAUT)
Cue Health (NASDAQ:HLTH – Get Rating) and Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Cue Health and Nautilus Biotechnology, as provided by MarketBeat.com.
Get Cue Health alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Health | 0 | 1 | 3 | 0 | 2.75 |
| Nautilus Biotechnology | 0 | 2 | 0 | 0 | 2.00 |
Cue Health currently has a consensus price target of $7.00, suggesting a potential upside of 139.73%. Nautilus Biotechnology has a consensus price target of $4.00, suggesting a potential upside of 158.06%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cue Health.
Insider and Institutional Ownership
37.9% of Cue Health shares are owned by institutional investors. Comparatively, 46.1% of Nautilus Biotechnology shares are owned by institutional investors. 29.4% of Cue Health shares are owned by insiders. Comparatively, 41.3% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.Profitability
This table compares Cue Health and Nautilus Biotechnology's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cue Health | -24.25% | -12.29% | -8.93% |
| Nautilus Biotechnology | N/A | -17.79% | -16.17% |
Risk & Volatility
Cue Health has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Valuation & Earnings
This table compares Cue Health and Nautilus Biotechnology's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Health | $618.11 million | 0.71 | $86.42 million | ($0.88) | -3.32 |
| Nautilus Biotechnology | N/A | N/A | -$50.31 million | ($0.49) | -3.16 |
Cue Health has higher revenue and earnings than Nautilus Biotechnology. Cue Health is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Cue Health beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.
About Cue Health
(Get Rating)
Cue Health Inc., a healthcare technology company, designs and develops diagnostic platform for diagnostic tests for individuals, enterprises, healthcare providers and payors, and public health agencies. The company offers Cue Integrated Care platform comprising hardware and software components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, a solution that allows integrations with third-party applications and sensors. It also provides COVID-19 testing kits for the Cue Health Monitoring System The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.
About Nautilus Biotechnology
(Get Rating)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Cue Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Health and related companies with MarketBeat.com's FREE daily email newsletter.
Cue Health (NASDAQ:HLTH – Get Rating) and Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
CUE Health(纳斯达克：HLTH-GET评级)和鹦鹉螺生物科技(纳斯达克：NAUT-GET评级)都是小盘医疗公司，但哪种投资更好？我们将根据两家公司的股息、风险、机构持股、分析师建议、收益、估值和盈利能力来比较它们的实力。
Analyst Recommendations
分析师建议
This is a breakdown of current ratings and recommmendations for Cue Health and Nautilus Biotechnology, as provided by MarketBeat.com.
这是由MarketBeat.com提供的对Cue Health和Nautilus Biotech的当前评级和推荐的细分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Health | 0 | 1 | 3 | 0 | 2.75 |
| Nautilus Biotechnology | 0 | 2 | 0 | 0 | 2.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 球杆健康 | 0 | 1 | 3 | 0 | 2.75 |
| 鹦鹉螺生物技术 | 0 | 2 | 0 | 0 | 2.00 |
Cue Health currently has a consensus price target of $7.00, suggesting a potential upside of 139.73%. Nautilus Biotechnology has a consensus price target of $4.00, suggesting a potential upside of 158.06%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cue Health.
Cue Health目前的共识目标价为7美元，暗示潜在涨幅为139.73。鹦鹉螺生物技术公司的一致目标价为4.00美元，这意味着潜在的上涨幅度为158.06。考虑到鹦鹉螺生物技术更有可能的上行空间，分析师们显然认为鹦鹉螺生物技术比Cue Health更有利。
Insider and Institutional Ownership
内部人与机构持股
Profitability
盈利能力
This table compares Cue Health and Nautilus Biotechnology's net margins, return on equity and return on assets.
此表比较了Cue Health和Nautilus Biotech的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Cue Health | -24.25% | -12.29% | -8.93% |
| Nautilus Biotechnology | N/A | -17.79% | -16.17% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 球杆健康 | -24.25% | -12.29% | -8.93% |
| 鹦鹉螺生物技术 | 不适用 | -17.79% | -16.17% |
Risk & Volatility
风险与波动性
Cue Health has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Cue Health的贝塔系数为1.12，这意味着其股价的波动性比标准普尔500指数高12%。相比之下，鹦鹉螺生物技术公司的贝塔系数为0.84，这意味着其股价的波动性比标准普尔500指数低16%。
Valuation & Earnings
估值与收益
This table compares Cue Health and Nautilus Biotechnology's top-line revenue, earnings per share (EPS) and valuation.
该表格比较了Cue Health和Nautilus Biotech的营收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Health | $618.11 million | 0.71 | $86.42 million | ($0.88) | -3.32 |
| Nautilus Biotechnology | N/A | N/A | -$50.31 million | ($0.49) | -3.16 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 球杆健康 | 6.1811亿美元 | 0.71 | 8642万美元 | ($0.88) | -3.32 |
| 鹦鹉螺生物技术 | 不适用 | 不适用 | -5,031万元 | ($0.49) | -3.16 |
Cue Health has higher revenue and earnings than Nautilus Biotechnology. Cue Health is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Cue Health的收入和收益高于鹦鹉螺生物技术公司。Cue Health的市盈率低于鹦鹉螺生物科技，表明它目前是两只股票中更负担得起的一只。
Summary
摘要
Cue Health beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.
Cue Health在两只股票之间进行比较的13个因素中，有7个超过了Nautilus Biotech。
About Cue Health
关于Cue Health
(Get Rating)
(获取评级)
Cue Health Inc., a healthcare technology company, designs and develops diagnostic platform for diagnostic tests for individuals, enterprises, healthcare providers and payors, and public health agencies. The company offers Cue Integrated Care platform comprising hardware and software components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, a solution that allows integrations with third-party applications and sensors. It also provides COVID-19 testing kits for the Cue Health Monitoring System The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.
CUE Health Inc.是一家医疗保健技术公司，为个人、企业、医疗保健提供者和付款人以及公共卫生机构设计和开发诊断测试诊断平台。该公司提供由硬件和软件组件组成的Cue集成护理平台，例如由Cue Reader(便携式可重复使用的读取器)、Cue Cartridge(一次性测试墨盒)和Cue Wand(样本采集棒)组成的Cue Health Monitor System；Cue Data and Innovation Layer，具有基于云的数据和分析能力的解决方案；Cue虚拟护理交付应用，包括Cue Health App和Cue Enterprise Dashboard；以及Cue Ecoessis集成和应用，允许与第三方应用和传感器集成。它还为CUE健康监测系统提供新冠肺炎检测试剂盒，该公司前身为CUE Inc.，并于2017年12月更名为Cue Health Inc.。CUE Health Inc.成立于2010年，总部设在加利福尼亚州圣地亚哥。
About Nautilus Biotechnology
关于鹦鹉螺生物技术
(Get Rating)
(获取评级)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
鹦鹉螺生物技术公司是一家处于发展阶段的生命科学公司，致力于创建一种量化和解锁蛋白质组复杂性的平台技术。它开发了Nautilus Platform，这是一个蛋白质组学平台，包括由仪器、消耗品和软件分析组成的端到端解决方案。该公司成立于2016年，总部位于华盛顿州西雅图。
Receive News & Ratings for Cue Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Health and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Cue Health Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cue Health和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧